These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 32269572)
1. Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease. Fitzpatrick EA; Wang J; Strome SE Front Immunol; 2020; 11():496. PubMed ID: 32269572 [TBL] [Abstract][Full Text] [Related]
2. rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs. Spirig R; Campbell IK; Koernig S; Chen CG; Lewis BJB; Butcher R; Muir I; Taylor S; Chia J; Leong D; Simmonds J; Scotney P; Schmidt P; Fabri L; Hofmann A; Jordi M; Spycher MO; Cattepoel S; Brasseit J; Panousis C; Rowe T; Branch DR; Baz Morelli A; Käsermann F; Zuercher AW J Immunol; 2018 Apr; 200(8):2542-2553. PubMed ID: 29531170 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages. Nagelkerke SQ; Dekkers G; Kustiawan I; van de Bovenkamp FS; Geissler J; Plomp R; Wuhrer M; Vidarsson G; Rispens T; van den Berg TK; Kuijpers TW Blood; 2014 Dec; 124(25):3709-18. PubMed ID: 25352126 [TBL] [Abstract][Full Text] [Related]
6. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058 [TBL] [Abstract][Full Text] [Related]
7. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors. Ortiz DF; Lansing JC; Rutitzky L; Kurtagic E; Prod'homme T; Choudhury A; Washburn N; Bhatnagar N; Beneduce C; Holte K; Prenovitz R; Child M; Killough J; Tyler S; Brown J; Nguyen S; Schwab I; Hains M; Meccariello R; Markowitz L; Wang J; Zouaoui R; Simpson A; Schultes B; Capila I; Ling L; Nimmerjahn F; Manning AM; Bosques CJ Sci Transl Med; 2016 Nov; 8(365):365ra158. PubMed ID: 27856797 [TBL] [Abstract][Full Text] [Related]
8. 7th International Immunoglobulin Conference: Mechanisms of action. Basta M; Branch DR Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):87-8. PubMed ID: 25546774 [TBL] [Abstract][Full Text] [Related]
9. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. Anthony RM; Ravetch JV J Clin Immunol; 2010 May; 30 Suppl 1():S9-14. PubMed ID: 20480216 [TBL] [Abstract][Full Text] [Related]
10. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants. Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484 [TBL] [Abstract][Full Text] [Related]
16. Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors. Blundell PA; Le NPL; Allen J; Watanabe Y; Pleass RJ J Biol Chem; 2017 Aug; 292(31):12994-13007. PubMed ID: 28620050 [TBL] [Abstract][Full Text] [Related]